Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2004

View Archived Issues

Efficacy and safety of tacrolimus in fistulizing Crohn's disease

Combination of CCR5 receptor antagonist and ciclosporin effective against allograft rejection

Novel inducible nitric oxide synthase inhibitor promising against graft rejection

Further data on DepoMorphine in postoperative pain control

Efficacy and pharmacokinetics of Oxytrex in patients with chronic osteoarthritic pain

Studies show pregabalin to be safe and effective in treating postherpetic neuralgia

Enrollment under way in phase I study of NQO2 anticancer therapy

Potent and selective CCR5 antagonists effective against graft rejection in monkey

Novel CDK2/cyclin A inhibitor effective antitumor agent in vivo

Novel dual lipid synthesis inhibitor effective for metabolic syndrome and dyslipidemia

Yamanouchi and Fujisawa sign definitive merger agreement to form Astellas Pharma

Australian approval for Remodulin in pulmonary arterial hypertension

Acceptance of Onco TCS NDA triggers payment to Elan

New European phase III trial for Zadaxin triple therapy in HCV

Genetronics and Merck in agreement for MedPulser DNA Delivery System

Approval letter for anidulafungin

Ketek 99% effective in vitro against S. pneumoniae bacteria

Sinovac Biotech commences phase I testing of SARS vaccine

Additional analysis of response data from phase III Dacogen study in MDS

Nadixa launched in Germany

AstraZeneca confirms safety of Crestor

Plenaxis commercialization and development progress

Initial NICE recommendations for Glivec rebutted by Novartis

Rigel initiates phase I/II trial for R-803 in HCV

Oxigene updates Q1 development progress

Novel beta2-adrenoceptor agonist effective against bronchoconstriction in vivo

New PARP inhibitors for acute brain infarction developed at Mitsubishi Pharma

Ono scientists identify novel edg2 receptor antagonists

Dual dopamine D2/5-HT1A agonists with potential as antiparkinsonian agents

New GABA-A receptor modulators in early development at Neurogen

Ono claims new prostaglandin derivatives for use in bone disorders

Ube scientists prepare and test novel p38 MAP kinase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...